海南再有79種集中採購藥品落地使用 25品種降幅超過八成
據《海南日報》從省醫療保障局獲悉,海南省將於今日(10日)起正式執行國家組織第四批集中採購、「六省二區」省際聯盟和「十一省」省際聯盟藥品集中採購等三個批次中選結果,涉及79個集中採購藥品,三個批次價格平均降幅分別為44.56%、77.38%和71.45%,降幅超過80%的品種達到25個,涵蓋抗癌藥、平喘藥、抗生素、滴眼液、糖尿病和心腦血管用藥等多個常用藥品種,百姓用藥成本進一步降低。
據悉,海南省自2019年12月以來,已落地執行四個批次共計157種國家組織藥品集中採購中選結果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.